Hirotsu Bio Science
Developed N-Nose, a non-invasive cancer screening product using nematode worms to detect early-stage cancers through urine samples.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
* | N/A | Late VC | |
| Total Funding | 000k | ||
Related Content
Hirotsu Bio Science is a pioneering biotechnology company specializing in cancer diagnostics and treatment. The company leverages advanced nematode-based technology to detect cancer at early stages, providing a significant advantage in personalized treatment plans. Operating primarily in the healthcare and biotechnology sectors, Hirotsu Bio Science serves medical institutions, research organizations, and healthcare providers. The company's business model revolves around the development and commercialization of diagnostic tests, particularly the N-NOSE test, which uses nematodes to detect cancer biomarkers in urine samples. Revenue is generated through the sale of these diagnostic tests and related services.
Hirotsu Bio Science's market includes both domestic and international clients, with a focus on expanding its reach globally. The company aims to revolutionize cancer diagnostics by offering a non-invasive, accurate, and cost-effective solution for early cancer detection. By integrating cutting-edge research with practical applications, Hirotsu Bio Science is positioned to make a significant impact on the healthcare industry.
Keywords: cancer diagnostics, nematode technology, early detection, personalized treatment, N-NOSE test, biotechnology, healthcare, medical institutions, non-invasive, biomarkers.